An update on the management of sporadic desmoid-type fibromatosis:a european consensus initiative between sarcoma patients euronet (spaen) and european organization for research and treatment of cancer (eortc)/soft tissue and bone sarcoma group (stbsg)
| Autor: | B. Kasper, C. Baumgarten, J. Garcia, S. Bonvalot, R. Haas, F. Haller, P. Hohenberger, N. Penel, C. Messiou, W.T. van der Graaf, A. Gronchi, S. Bauer, J.Y. Blay, F. van Coevorden, P. Dileo, H.R. Dürr, M. Fiore, V. Grünwald, R. Jones, I. Judson, C. Kettelhack, K. Kopeckova, A. Lazar, L.H. Lindner, J. Martin-Broto, P. Rutkowski, S. Stacchiotti, E. Stoeckle, C. Valverde, K. Verhoef, E. Wardelmann, M. Wartenberg |
|---|---|
| Přispěvatelé: | CHU Lille, Université de Lille, University of Heidelberg, Medical Faculty, METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, Institut Curie [Paris], Antoni van Leeuwenhoek Hospital, Friedrich-Alexander Universität Erlangen-Nürnberg [FAU], Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS], The institute of cancer research [London], Molecular Targeting Unit, Department of Research [Fondazione IRCCS Istituto Nazionale dei Tumori, Milan], Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Fondazione IRCCS Istituto Nazionale Tumori - National Cancer Institute [Milan] |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
desmoid medicine.medical_treatment [SDV]Life Sciences [q-bio] Aggressive fibromatosis Disease aggressive fibromatosis 0302 clinical medicine Mesh:Aggressive/diagnosis Patient advocacy groups Randomized Controlled Trials as Topic Fibromatosis Hematology treatment algorithm 3. Good health Fibromatosis Aggressive Oncology 030220 oncology & carcinogenesis Sarcoma Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] medicine.medical_specialty Reviews Bone Sarcoma EORTC/STBSG patient advocacy groups SPAEN 03 medical and health sciences SDG 3 - Good Health and Well-being medicine Treatment algorithm Humans Mesh:Aggressive/genetics Desmoid Mesh:Fibromatosis business.industry General surgery Mesh:Aggressive/therapy Cancer Mesh:Randomized Controlled Trials as Topic medicine.disease Surgery Radiation therapy Mesh:Humans 030104 developmental biology Position paper business |
| Zdroj: | Annals of Oncology Annals of Oncology, Elsevier, 2017, Annals of oncology official journal of the European Society for Medical Oncology, 28, pp.2399-2408. ⟨10.1093/annonc/mdx323⟩ Digital.CSIC. Repositorio Institucional del CSIC instname Annals of Oncology, 28, 2399-2408 Annals of Oncology, 2017, Annals of oncology official journal of the European Society for Medical Oncology, 28, pp.2399-2408. ⟨10.1093/annonc/mdx323⟩ Annals of Oncology, 28, 10, pp. 2399-2408 |
| ISSN: | 0923-7534 1569-8041 |
| DOI: | 10.1093/annonc/mdx323⟩ |
| Popis: | Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this disease. Therefore, in 2015 the European Desmoid Working Group published a position paper giving recommendations on the treatment of this intriguing disease. Here, we present an update of this consensus approach based on professionals’ AND patients’ expertise following a round table meeting bringing together sarcoma experts from the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group with patients and patient advocates from Sarcoma PAtients EuroNet. In this paper, we focus on new findings regarding the prognostic value of mutational analysis in desmoid-type fibromatosis patients and new systemic treatment options. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|